Tuberculosis Therapeutics Market Size

Tuberculosis Therapeutics Market size was valued at around USD 2 billion in 2023 and is estimated to grow at 4.1% CAGR from 2024 to 2032. The rising prevalence of Tuberculosis (TB) globally is a significant driver for the growth of the market. TB remains a major global health threat, with a high burden in many parts of the world, particularly in developing countries and regions with high population density and limited healthcare access.

For instance, according to the World Health Organization (WHO), in 2020, an estimated 10 million people fell ill with TB globally. This number includes 5.6 million men, 3.2 million women, and 1.2 million children. This demonstrates a persistently high level of TB incidence, despite efforts to control the disease. Ongoing investments in research, development, and public health initiatives are crucial in addressing the challenges posed by TB and advancing treatment options to improve outcomes for patients worldwide.  

Tuberculosis (TB) therapeutics refer to the range of medical treatments and interventions aimed at combating Tuberculosis infections, caused primarily by Mycobacterium Tuberculosis bacteria. TB is a contagious airborne disease that primarily affects the lungs but can also impact other parts of the body.